Aptose Non Current Assets Total vs Intangible Assets Analysis
APTO Stock | USD 0.99 0.04 4.21% |
Aptose Biosciences financial indicator trend analysis is way more than just evaluating Aptose Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptose Biosciences is a good investment. Please check the relationship between Aptose Biosciences Non Current Assets Total and its Intangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.
Non Current Assets Total vs Intangible Assets
Non Current Assets Total vs Intangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptose Biosciences Non Current Assets Total account and Intangible Assets. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Aptose Biosciences' Non Current Assets Total and Intangible Assets is -0.14. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of Aptose Biosciences, assuming nothing else is changed. The correlation between historical values of Aptose Biosciences' Non Current Assets Total and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Aptose Biosciences are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Non Current Assets Total i.e., Aptose Biosciences' Non Current Assets Total and Intangible Assets go up and down completely randomly.
Correlation Coefficient | -0.14 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Most indicators from Aptose Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptose Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.At this time, Aptose Biosciences' Selling General Administrative is very stable compared to the past year. As of the 5th of June 2024, Sales General And Administrative To Revenue is likely to grow to 47.11, while Issuance Of Capital Stock is likely to drop about 5.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 94K | 788K | 1.4M | 1.5M | Interest Income | 94K | 788K | 1.4M | 1.5M |
Aptose Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Aptose Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aptose Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 100.5M | 126.3M | 82.5M | 51.0M | 12.9M | 12.3M | |
Other Current Liab | 3.1M | 4.1M | 6.0M | 5.7M | 13.9M | 14.6M | |
Total Current Liabilities | 5.5M | 6.8M | 8.2M | 12.3M | 15.2M | 16.0M | |
Total Stockholder Equity | 93.9M | 118.9M | 74.2M | 37.7M | (2.9M) | (2.7M) | |
Property Plant And Equipment Net | 1.7M | 1.2M | 788K | 1.5M | 1.1M | 574.3K | |
Net Debt | (78.3M) | (116.3M) | (38.5M) | (35.7M) | (8.2M) | (8.6M) | |
Retained Earnings | (301.9M) | (357.2M) | (422.5M) | (464.3M) | (512.9M) | (487.3M) | |
Accounts Payable | 2.0M | 2.2M | 1.7M | 6.3M | 3.5M | 3.7M | |
Cash | 79.8M | 117.4M | 39.1M | 37.0M | 9.2M | 15.8M | |
Non Current Assets Total | 1.7M | 1.2M | 788K | 1.5M | 1.1M | 1.7M | |
Cash And Short Term Investments | 97.6M | 122.4M | 79.1M | 47.0M | 9.2M | 8.7M | |
Common Stock Shares Outstanding | 3.3M | 5.5M | 5.9M | 6.2M | 6.8M | 7.1M | |
Short Term Investments | 798K | 440K | 17.8M | 5M | 40.0M | 10.0M | |
Liabilities And Stockholders Equity | 100.5M | 126.3M | 82.5M | 51.0M | 12.9M | 12.3M | |
Non Current Liabilities Total | 1.0M | 535K | 115K | 1.0M | 617.8K | 586.9K | |
Other Current Assets | 141K | 129K | 133K | 257K | 2.6M | 2.8M | |
Other Stockholder Equity | 34.6M | 50.9M | 63.7M | 68.9M | 71.8M | 75.4M | |
Total Liab | 6.6M | 7.3M | 8.3M | 13.3M | 15.8M | 16.6M | |
Property Plant And Equipment Gross | 1.7M | 1.2M | 323K | 211K | 3.9M | 4.1M | |
Total Current Assets | 98.8M | 125.1M | 81.7M | 49.5M | 11.8M | 11.2M | |
Non Currrent Assets Other | (94.0) | (48.0) | 465K | 1.3M | 1.2M | 1.2M | |
Intangible Assets | 1.0 | 142.0 | 94.0 | 48.0 | 43.2 | 41.04 | |
Net Tangible Assets | 93.8M | 118.9M | 74.2M | 37.7M | 43.4M | 45.6M | |
Common Stock Total Equity | 365.5M | 429.5M | 437.4M | 437.5M | 503.1M | 528.3M | |
Retained Earnings Total Equity | (301.9M) | (357.2M) | (422.5M) | (464.3M) | (417.9M) | (397.0M) | |
Common Stock | 365.5M | 429.5M | 437.4M | 437.5M | 442.5M | 231.4M | |
Property Plant Equipment | 1.6M | 1.1M | 788K | 211K | 189.9K | 364.1K | |
Capital Surpluse | 34.6M | 50.9M | 63.7M | 68.9M | 79.2M | 51.4M | |
Net Invested Capital | 93.9M | 118.9M | 74.2M | 37.7M | (2.9M) | (2.8M) | |
Net Working Capital | 93.2M | 118.3M | 73.6M | 37.2M | (3.4M) | (3.2M) | |
Capital Stock | 365.5M | 429.5M | 437.4M | 437.5M | 444.8M | 435.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Aptose Stock
When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.09) | Return On Assets (1.02) | Return On Equity (2.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.